Abstract
Similar to the concept of personalized medicine based on patients’ genetic differences, treatment of infectious diseases involves individualizing therapy according to genetic differences in infectious agents. The main example is that of HIV infection. There are two variable factors in HIV/AIDS – how people respond to the HIV and how HIV responds to drugs. Research in vaccinology is playing an important role in relation to immunology of HIV/AIDS.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrade A, Flexner C (2004) Genes, ethnicity, and efavirenz response: clinical pharmacology update from the 11th CROI. Hopkins HIV Rep 16:1–7
Aurora R, Donlin M, Cannon NA et al (2009) Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 119:225–236
Camilleri M (2007) Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. Neurogastroenterol Motil 19(s2):40–45
Chaussabel D, Allman W, Mejias A et al (2005) Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci 1062:146–154
Cobb JP, Mindrinos MN, Miller-Graziano C et al (2005) Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci USA 102:4801–4806
Dionne RA, Bartoshuk L, Mogil J, Witter J (2005) Individual responder analyses for pain: does one pain scale fit all? Trends Pharmacol Sci 26:125–130
Fu Liang NG, Holt DW, MacPhee I (2007) Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother 8:2045–2058
Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637–639
Israel E, Chinchilli VM, Ford JG et al (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364:1505–1512
Jain KK (2009l) Textbook of hyperbaric medicine, 5th edn, Hogrefe & Huber, Göttingen.
Kim S, Poursine-Laurent J, Truscott SM et al (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709–713
Lugogo NL, Ginsburg GS, Que LG (2007) Genetic profiling and tailored therapy in asthma: are we there yet? Curr Opin Mol Ther 9:528–537
Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney International 67:1704–1709
Plenge RM, Seielstad M, Padyukov L et al (2007) TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide study. N Engl J Med 357:1199–1209
Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293
Rodriguez-Torres M, Jeffers LJ, Sheikh MY et al (2009) Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 360:257–267
Ross JR, Rutter D, Welsh K et al (2005) Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 5:324–336
Rudnicki M, Mayer G (2003) Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease – pathophysiological considerations. Pharmacogenomics 4:153–162
Rutter JL (2006) Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J 8:E174–E184
Takei Y, Sawada T, Sameshima S, Nagasako K (2001) Post-genome challenges against inflammatory bowel diseases. Nippon Rinsho 59:180–184
Taniguchi A, Urano W, Tanaka E, Kamatani N (2007) Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis. Nippon Rinsho 65:371–379
Tozzi V, Libertone R, Liuzzi G (2008) HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr HIV Res 6:544–554
Werely CJ, Donald PR, van Helden PD (2007) NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients. Personal Med 4:123–131
Williams DG, Patel A, Howard RF (2002) Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 89:839–845
Woolf CJ; American College of Physicians; American Physiological Society (2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140:441–451
Yudkin P, Munafo M, Hey K et al (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328:989–990
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2009). Personalized Management of Miscellaneous Disorders. In: Textbook of Personalized Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0769-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0769-1_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0768-4
Online ISBN: 978-1-4419-0769-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)